However, even with the highly effective third generation of EGFR inhibitors, their anticancer effects can gradually diminish, and a population of cancer cells with additional resistance often emerges, presenting critical challenges that need to be addressed (Leonetti et al., 2019; Ramalingam et al., 2020; Cooper et al., 2022; Fu et al., 2022; Gomatou et al., 2023). Here, EGFR is linked to cancer.